- Home
- PAII vs RLMD Comparison
PAII vs RLMD Comparison
Compare PAII & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAII | RLMD |
|---|---|---|
| Founded | 2025 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.8M | 319.7M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | PAII | RLMD |
|---|---|---|
| Price | $10.13 | $6.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.25 |
| AVG Volume (30 Days) | 54.2K | ★ 542.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $9.92 | $0.24 |
| 52 Week High | $10.17 | $5.12 |
Technical Indicators
Market Signals| Indicator | PAII | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 78.44 |
| Support Level | $10.04 | $3.65 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.03 | 0.45 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 75.00 | 95.70 |
Price Performance
Historical ComparisonAbout PAII Pyrophyte Acquisition Corp. II Class A Ordinary Shares
Pyrophyte Acquisition Corp II is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.